Evidence map›Paper›PMID 40998875›Full record

ArticleScientific reports2025

Molecular dynamics insights into the redox effects on PD-1/PD-L1 and PD-1/PD-L2 interactions.

Rasulbek Mashalov, Zulfizar Toshpulatova, Zhitong Chen, Jamoliddin Razzokov

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rasulbek MashalovLaboratory of Experimental Biophysics, Centre for Advanced Technologies, Universitet 7, 100174, Tashkent, Uzbekistan. rasulmashalov14@gmail.com.
Zulfizar ToshpulatovaLaboratory of Experimental Biophysics, Centre for Advanced Technologies, Universitet 7, 100174, Tashkent, Uzbekistan.
Zhitong ChenAdvanced Therapeutic Center, National Innovation Center for Advanced Medical Devices, Shenzhen, China.
Jamoliddin RazzokovInstitute of Fundamental and Applied Research, National Research University TIIAME, Kori Niyoziy 39, 100000, Tashkent, Uzbekistan. jrazzokov@gmail.com.

Funding

Agency for Innovative Development of the Republic of Uzbekistan № AL-59-21122141National Key Research and Development Program of China 2022YFE0126000
6 · The paper itself

Abstract

The PD-1/PD-L1/PD-L2 immune checkpoint plays a critical role in regulating immune responses, and its dysfunction is implicated in immune evasion by cancer cells. Cold atmospheric plasma (CAP) has emerged as a promising cancer therapeutic modality with the potential to modulate immune checkpoints. This study employs molecular dynamics (MD) simulations to investigate the impact of CAP-induced oxidation on the interactions between PD-1 and its ligands, PD-L1 and PD-L2. We simulated the PD-1/PD-L1 and PD-1/PD-L2 complexes under different oxidation levels by oxidizing vulnerable residues within the interaction site of the ligands. MD simulations combined with enhanced sampling methods revealed that increasing oxidation levels leads to weaken the binding affinity between PD-1 and both PD-L1/PD-L2. These findings suggest that CAP may offer a novel strategy for enhancing anti-tumor immunity. This computational study provides valuable insights into the molecular mechanisms underlying CAP's effects on immune regulation and highlights its potential for cancer immunotherapy.

Indexed as

B7-H1 AntigenMolecular Dynamics SimulationProgrammed Cell Death 1 Ligand 2 ProteinProgrammed Cell Death 1 ReceptorHumansLigandsOxidation-ReductionPlasma GasesProtein BindingB7-H1 AntigenCD274 protein, humanLigandsPDCD1LG2 protein, humanPDCD1 protein, humanPlasma GasesProgrammed Cell Death 1 Ligand 2 ProteinProgrammed Cell Death 1 ReceptorImmune checkpoint proteinsImmunogenic cell deathPD-1-PD-L1/PD-L2Potential mean forceUmbrella sampling

Identifiers

PMID40998875
PMCPMC12464212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.